Clovis Oncology Inc. (CLVS) Shares Down 2.4%
Clovis Oncology Inc. (NASDAQ:CLVS) traded down 2.4% on Friday . The company traded as low as $14.16 and last traded at $14.19, with a volume of 271,395 shares changing hands. The stock had previously closed at $14.54.
A number of equities research analysts have recently weighed in on the company. Piper Jaffray Cos. reissued a “hold” rating on shares of Clovis Oncology in a research note on Sunday, May 8th. Credit Suisse Group AG assumed coverage on Clovis Oncology in a research note on Monday, April 18th. They issued an “outperform” rating for the company. WallachBeth Capital lowered their target price on Clovis Oncology from $30.00 to $22.00 and set a “hold” rating for the company in a research note on Monday, May 9th. Zacks Investment Research lowered Clovis Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday, May 10th. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of Clovis Oncology in a research note on Wednesday, April 13th. Seven equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Clovis Oncology currently has an average rating of “Hold” and a consensus target price of $29.25.
The stock’s market capitalization is $544.68 million. The stock has a 50-day moving average of $14.29 and a 200 day moving average of $17.34.
Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.39) by $0.22. During the same period in the prior year, the firm earned ($1.86) earnings per share. The firm’s revenue was up NaN% on a year-over-year basis. On average, equities research analysts expect that Clovis Oncology Inc. will post ($8.00) earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of CLVS. California State Teachers Retirement System boosted its stake in shares of Clovis Oncology by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 51,609 shares of the biopharmaceutical company’s stock valued at $1,806,000 after buying an additional 889 shares during the period. ProShare Advisors LLC boosted its stake in shares of Clovis Oncology by 9.5% in the fourth quarter. ProShare Advisors LLC now owns 36,129 shares of the biopharmaceutical company’s stock valued at $1,265,000 after buying an additional 3,125 shares during the last quarter. Trexquant Investment LP bought a new stake in shares of Clovis Oncology during the fourth quarter valued at $3,170,000. Finally, Rhumbline Advisers boosted its stake in shares of Clovis Oncology by 6.6% in the fourth quarter. Rhumbline Advisers now owns 30,237 shares of the biopharmaceutical company’s stock valued at $1,058,000 after buying an additional 1,880 shares during the last quarter.
Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.